Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Recently, Merck and Hansoh Pharmaceutical announced that they have signed a global exclusive licensing agreement for HS-10535, an oral small molecule GLP-1 receptor agonist currently in preclinical research
The animals were group-housed until one week before treatment initiation, after which they were given daily subcutaneous injections of vehicle or Cagrilintide at doses of 0.3, 3, or 30 nmol/kg for 21 days
Common side effects include nausea, decreased appetite (which can aid in weight loss), and occasional mild constipation, diarrhea, or stomach discomfort
44 Statistical Analysis Results are expressed as the means (s.e.m.) of 34 separate cell preparations
Lawsuits point to evidence that drugmakers were aware of more long-term risks than they disclosed, continuing to market GLP-1 drugs as safe for widespread use
10.1007/s10620-008-0332-9 130 SkorjanecS.KokotA.DrmicD.RadicB.SeverM.KlicekR.et al (2015)
US$ 25.75
US$ 20.55
US$ 20.70
